These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32749204)

  • 21. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.
    Vrankar M; Unk M
    Radiol Oncol; 2018 Oct; 52(4):365-369. PubMed ID: 30367809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
    Hodi FS; Hwu WJ; Kefford R; Weber JS; Daud A; Hamid O; Patnaik A; Ribas A; Robert C; Gangadhar TC; Joshua AM; Hersey P; Dronca R; Joseph R; Hille D; Xue D; Li XN; Kang SP; Ebbinghaus S; Perrone A; Wolchok JD
    J Clin Oncol; 2016 May; 34(13):1510-7. PubMed ID: 26951310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
    Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
    JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
    Guiard E; Baldini C; Pobel C; Assi T; Bernard-Tessier A; Martin-Romano P; Hollebecque A; Verlingue L; Geraud A; Michot JM; Armand JP; Soria JC; Massard C; Ammari S
    Eur J Cancer; 2022 May; 167():42-53. PubMed ID: 35378410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Monitoring of immunotherapy : Possibilities and limitations].
    Schneider H; Illert AL; Bamberg F; Eisenblätter M
    Radiologe; 2020 Aug; 60(8):711-720. PubMed ID: 32710153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
    Won SE; Park HJ; Byun S; Pyo J; Kim JH; Choi CM; Lee JC; Lee DH; Kim SW; Yoon S; Kim KW
    Oncoimmunology; 2020 Jun; 9(1):1776058. PubMed ID: 32923136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in assessing solid tumor responses to immunotherapy.
    Chai LF; Prince E; Pillarisetty VG; Katz SC
    Cancer Gene Ther; 2020 Aug; 27(7-8):528-538. PubMed ID: 31822814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
    Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
    Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging of tumour response to immunotherapy.
    Dromain C; Beigelman C; Pozzessere C; Duran R; Digklia A
    Eur Radiol Exp; 2020 Jan; 4(1):2. PubMed ID: 31900689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
    Chen K; Sun B
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Petrelli F; Grizzi G; Ghidini M; Ghidini A; Ratti M; Panni S; Cabiddu M; Ghilardi M; Borgonovo K; Parati MC; Tomasello G; Barni S; Berruti A; Brighenti M
    J Immunother; 2020 Jan; 43(1):1-7. PubMed ID: 31574022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.
    Tsukamoto S; Mavrogenis AF; Masunaga T; Aiba H; Aso A; Honoki K; Fujii H; Kido A; Tanaka Y; Tanaka Y; Errani C
    Eur J Orthop Surg Traumatol; 2024 Aug; 34(6):2823-2833. PubMed ID: 38836904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.
    Abbasi AW; Westerlaan HE; Holtman GA; Aden KM; van Laar PJ; van der Hoorn A
    Clin Neuroradiol; 2018 Sep; 28(3):401-411. PubMed ID: 28466127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of pseudoprogression in patients with glioblastoma.
    Kucharczyk MJ; Parpia S; Whitton A; Greenspoon JN
    Neurooncol Pract; 2017 Jun; 4(2):120-134. PubMed ID: 31386017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.
    Martin-Romano P; Castanon E; Ammari S; Champiat S; Hollebecque A; Postel-Vinay S; Baldini C; Varga A; Michot JM; Vuagnat P; Marabelle A; Soria JC; Ferté C; Massard C
    Cancer Med; 2020 Apr; 9(8):2643-2652. PubMed ID: 32074405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
    Zhou L; Zhang M; Li R; Xue J; Lu Y
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3269-3279. PubMed ID: 32857178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
    Le Rhun E; Wolpert F; Fialek M; Devos P; Andratschke N; Reyns N; Regli L; Dummer R; Mortier L; Weller M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32747372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.